The Specialist Forum Volume 13 No 11 November 2013 | Page 85

Zuvamor ® March 2013 Dear Healthcare Provider, AstraZeneca Pharmaceuticals and Aspen are pleased to announce the launch of Zuvamor® (rosuvastatin), making the original rosuvastatin more accessible to patients. Zuvamor® is indicated for patients with primary hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia or familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid lowering treatments. 1 Please see below for prices approved by the Department of Health: Nappi code Product Name Active Ingredient Strength Pack Size Dosage Form NEW SEP (ex VAT) 717520001 Zuvamor® 10 Rosuvastatin 10 mg 28 Tabs R 138.41 717521001 Zuvamor® 20 Rosuvastatin 20 mg 28 Tabs R 200.35 717522001 Zuvamor® 40 Rosuvastatin 40 mg 28 Tabs R 243.51 Should you require more information, please contact Claude Hadebe (011) 239-3412 or our Medical Hotline on Should you require more information, please contact Lindi Kekana on on (011) 239-3480 or our MedicalHotline on 0800 118 088. 0800118 088. Kind Regards, Kind Regards, Lindi Kekana Claude Hadebe Saras Rosin Senior Marketing Business Development AstraZeneca Pharmaceuticals Head of Marketing: Pharma Commercial Manager: Aspen Pharmacare Cardiovascular Portfolio Marketing Aspen Pharmacare Reference: 1. Zuvamor® approved package insert. S4 Zuvamor® 10. Reg. No: 36/7.5/0353; Zuvamor® 20. Reg. No: 36/7.5/0354; Zuvamor® 40. Reg. No: 36/7.5/0355. Each tablet contains 10 mg, 20 mg or 40 mg of rosuvastatin respectively as rosuvastatin calcium. For further details please refer to the package insert approved by the medicines regulatory authority. Applicant: AstraZeneca Pharmaceuticals (Pty) Limited. Co. Reg. No./Nr. 1992/005854/07, 5 Leeuwkop Road, Sunninghill, 2157. Marketed by: Aspen Pharmacare. Building 12, Healthcare Park, Woodlands Drive, Woodmead, 2191. Medical Information Hotline 0800 118 088. A 16079 03/13. ZUM 03/13/002. Page 26 July 2013 | The Specialist Forum